Format

Send to:

Choose Destination
See comment in PubMed Commons below
Drugs Today (Barc). 2010 Aug;46(8):581-7. doi: 10.1358/dot.2010.46.8.1500050.

Quetiapine fumarate for schizophrenia and bipolar disorder in young patients.

Author information

  • 1Department of Neuroscience, University of Rome-Tor Vergata, Rome, Italy.

Abstract

During the past decade, there has been a substantial increase in the prescribing of antipsychotics to young patients for a variety of pediatric psychiatric disorders. Quetiapine (Seroquel®) received its initial indication from the U.S. Food and Drug Administration for treatment of schizophrenia in 1997, and it received its second indication for the treatment of mania-associated bipolar disorder in 2004. Currently, in young patients, authorized quetiapine indications are schizophrenia in individuals aged 13 or older and manic episodes associated with bipolar I disorder in children 10 to 17 years old. Quetiapine has different pharmacological actions and acts as an antagonist for following receptors: D(2) receptor, serotonin 5-HT(2A) also known as α(1)-adrenoceptor, histamine 1 receptor and muscarinic acetylcholine receptor. Several studies have shown its favorable profile of effectiveness and tolerability in young bipolar and schizophrenic patients. However, the current data make it very clear that the risks and benefits of this drug need to be weighed individually for each patient.

Copyright 2010 Prous Science, S.A.U. or its licensors. All rights reserved.

PMID:
20830318
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Prous Science
    Loading ...
    Write to the Help Desk